KRAS and colorectal carcinoma: In studying KRAS, PIK3CA and BRAF mutations together with MET and PTEN expression in colorectal primary tumors and corresponding metastases, Voutsina et al more recently concluded that metastatic lesions are the most appropriate tissues to analyze in order to determine the appropriate targeted therapies in metastatic CRC.